The International Journal of Biochemistry & Cell Biology
Medicine in focusLiver failure: basis of benefit of therapy with the molecular adsorbents recirculating system
Introduction
Liver failure may occur acutely without any underlying liver disease (acute liver failure, ALF), as an acute decompensation of chronic liver disease (‘acute-on-chronic’ liver failure, ACLF) or as a chronic decompensation of end-stage liver disease. In addition to the central hepatic failure, all the types are characterized by manifestations of end-organ dysfunctions, of which the most important are disturbances of circulation, renal and cerebral functions. In contrast to chronic decompensation of end-stage liver disease, ALF and ACLF have the potential of reversibility. An extracorporeal supportive therapy which can tide over the acute crisis (and, especially in ALF, act as a bridge to liver transplantation) is possibly life-saving (Sen et al., 2002, Sen et al., 2002), and the search for an effective liver support system continues. Essentially, two types are under development: bio-artificial devices, which use hepatocytes to perform the functions of the failing liver; and artificial devices, of which the one being tried extensively at present is the molecular adsorbents recirculating system (MARS), based on the principles of albumin dialysis.
Section snippets
Pathophysiology of liver failure
The mechanisms underlying the development of the multi-organ dysfunction of liver failure are complex, and as yet poorly understood. However, early studies demonstrating that cross-circulation between baboons and men with hepatic coma made the baboons sick (Abouna, 1968) led to the a ‘toxin hypothesis’ which suggests that most of the associated organ impairment is due to the accumulation of a variety of toxins as a result of impaired hepatic metabolism/detoxification. While ammonia, protein
Therapy: molecular adsorbents recirculating system (MARS)
Because most of the relevant toxins in liver failure are albumin bound, conventional haemodialysis/haemofiltration cannot effectively remove them. This has led to the development of an extracorporeal liver support system known as the molecular adsorbents recirculating system (Teraklin AG, Rostock, Germany). Using a hollow fibre dialysis module the patient’s blood is dialyzed across an albumin-impregnated polysulfone membrane with a pore size of 50 kDa, while at the same time maintaining a
Conclusion
MARS is an exciting tool for the treatment of liver failure, with its consistent effects in improving hyperbilirubinaemia and HE, along with some improvement of renal functions. Most importantly, survival may also be improved, but it has to be remembered that most of the studies till date have been small, and the majority uncontrolled. Also, very little is known about the exact mechanism by which MARS brings about these improvements. Currently, two multi-centre randomized controlled trials are
Conflict of interest statement
None of the authors have any financial conflict of interest with respect to MARS or Teraklin AG. We are, however, involved as part of a European multi-centre randomized controlled trial investigating the role of MARS in ‘acute-on-chronic’ liver failure.
References (22)
Cross-circulation between man and baboon in hepatic coma
Lancet
(1968)- et al.
Binding properties of human albumin modified by covalent binding of penicillin
Biochimica et Biophysica Acta
(2001) - et al.
Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study
Hepatology
(2002) - et al.
Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis
Journal of Hepatology
(2003) - et al.
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial
Liver Transplantation
(2000) - et al.
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study
Hepatology
(2002) Review article: Albumin in the treatment of liver diseases-new features of a classical treatment
Aliment Pharmacology & Therapeutics
(2002)- et al.
Modulation of arachidonic acid release and membrane fluidity by albumin in vascular smooth muscle and endothelial cells
Circulation Research
(1998) - et al.
Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation
American Journal of Respiration and Critical Care Medicine
(2000) Review article: Albumin as a drug-biological effects of albumin unrelated to oncotic pressure
Aliment Pharmacology & Therapeutics
(2002)
Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure. Part II. In vivo evaluation
Artificial Organs
Cited by (35)
The Effect of Molecular Adsorbent Recirculating System in Patients With Liver Failure: A Case Series of 44 Patients
2023, Transplantation ProceedingsPlasmafiltration-Adsorption-Dialysis System
2019, Critical Care Nephrology: Third EditionA non-adhesive hybrid scaffold from gelatin and gum Arabic as packed bed matrix for hepatocyte perfusion culture
2015, Materials Science and Engineering CCitation Excerpt :Such devices provide temporary support to liver and bridge the patient with liver transplantation or liver regeneration. Various approaches such as hemodialysis or perfusion through activated charcoal were considered as an extracorporeal support for Acute Liver Failure [1,2]. But these liver assist device (LAD) systems could not supplement the synthetic and metabolic functions of the normal liver.
Removal of albumin-bound toxins from albumin-containing solutions: Tryptophan fixed-bed adsorption on activated carbon
2010, Chemical Engineering Research and DesignCitation Excerpt :Indeed, these clinical conditions are associated with the accumulation in plasma of different toxins including not only water-soluble, low-molecular weight compounds, as in the case of renal failure, but also molecules that bind to albumin and other plasma proteins to form high-molecular weight complexes. Conventional dialysis over rather selective membranes, that is applied successfully in the management of renal failure patients, proved to be scarcely beneficial in the therapy of liver failure, reasonably because this process is ineffective for the clearance of the albumin-bound fraction of toxins (Hughes, 2002; Sen et al., 2003). Therefore, new detoxification processes have been developed with the specific aim of removing albumin-bound toxins, and different extracorporeal liver support devices (LSDs) implementing these processes have been already approved for clinical use in many countries or are under investigation (Jalan et al., 2004; Stegmayr, 2005; Rozga, 2006).
The Plasmafiltration-Adsorption-Dialysis System
2008, Critical Care Nephrology, Second EditionPoisoning: Kinetics to Therapeutics
2008, Critical Care Nephrology, Second Edition